GLAXOSMITHKLINE PHARMACEUTICALS LTD. - 500660 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Add Relating to Record date & AGM23-05-2024
23-05-2024
GLAXOSMITHKLINE PHARMACEUTICALS LTD. - 500660 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Advance intimation under Regulation 3922-05-2024
GLAXOSMITHKLINE PHARMACEUTICALS LTD. - 500660 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication21-05-2024
GSK Pharma Q4 Results Review - Sales Growth, Better Operating Leverage Drive Earning: Motilal Oswal
Aims to outperform industry; cost control to drive profitable growth20-05-2024
GLAXOSMITHKLINE PHARMACEUTICALS LTD. - 500660 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Analyst Meet Outcome17-05-2024
GLAXOSMITHKLINE PHARMACEUTICALS LTD. - 500660 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Analyst Meet Outcome17-05-2024
GLAXOSMITHKLINE PHARMACEUTICALS LTD. - 500660 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for year ended March 202417-05-2024
Q4FY24 Quarterly & FY24 Annual Result Announced for GlaxoSmithKline Pharmaceuticals Ltd.
Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q4FY24 & FY24 results: Q4FY24 Financial Highlights: Revenue for the quarter came in at Rs 911 crore recorded a growth of 16%. Profit before exceptional items and tax for the quarter at Rs 266 crore recorded a growth of 51% with EBITDA margins at 28%. FY24 Financial Highlights: The full year reported revenue was at Rs 3,407 crore, a growth of 6%, demonstrating positive growth driven by a strong volume recovery thereby offsetting NLEM (National List of Essential Medicines) impact. Profit before exceptional items and tax for the year at Rs 953 crore recorded a growth of 14% with EBITDA at 26.4% up by 150 bps. Commenting on the results for Q4 and FY 2023-24, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, “For Q4, we delivered a strong double-digit growth and a robust performance across our General Medicines, Specialty and Vaccines portfolio. Our General Medicines portfolio recorded strong double-digit growth of 12% for the quarter, driven by key focus brands Augmentin, Ceftum and Calpol. Despite the NLEM impact in previous quarters, all promoted brands outpaced their respective categories in growth and gained market share. Specialty portfolio led by Nucala and Trelegy has accelerated the momentum with highest patient recruitment in Q4. For the vaccines business, over the last two quarters, we have seen a steady upswing in both adult and paediatric segments. This business delivered a Q4 growth of 35%. We continue to build on the momentum generated with the launch of Shingrix (Zoster Vaccine Recombinant, Adjuvanted) as we drive expansion of the Adult Immunisation category in India with innovative go-to-market (GTM) strategies." Result PDF17-05-2024